Abstract 4564
Background
The current standard-of-care first-line therapy for patients (pts) with recurrent/metastatic cervical cancer (r/mCC) is paclitaxel/platinum ± bevacizumab (BEV). However, approximately 50% of pts who are eligible to receive this regimen do not respond to the treatment. Tissue factor (TF) is highly expressed in cervical cancer and is associated with poor prognosis. Tisotumab vedotin (TV) is an investigational first-in-class antibody-drug conjugate comprising a fully human monoclonal antibody targeting TF conjugated to the microtubule-disrupting agent monomethyl auristatin E via a protease-cleavable linker. Single-agent TV demonstrated encouraging antitumor activity (independent review committee–assessed confirmed ORR, 22%; median DOR, 6.0 mo) and a manageable safety profile in pts with previously treated r/mCC. innovaTV 205/ENGOT-cx8 (NCT03786081; GOG-3024) is a global, multicenter, open-label, phase 1/2 trial evaluating the safety and antitumor activity of TV in combination with BEV, pembrolizumab (PEM), or carboplatin (CBP) in pts with untreated and previously treated r/mCC. Results from the innovaTV 205 study will inform the further clinical development of TV in cervical cancer.
Trial design
Approximately 140 adult pts with recurrent or stage IVB squamous, adenosquamous, or adenocarcinoma of the cervix; measurable disease; and ECOG PS 0-1 will be enrolled. The phase 1 portion of the study will consist of 3 dose escalation cohorts for identification of the recommended phase 2 dose (RP2D) of TV with BEV, PEM, or CBP. The phase 2 portion will include 3 expansion cohorts. In the dose escalation cohorts, previously treated pts will receive escalating doses of TV (IV 1Q3W) in combination with escalating doses of BEV (IV 1Q3W), a fixed dose of PEM (IV 1Q3W), or a fixed dose of CBP (IV 1Q3W). In the expansion cohorts, pts who have not received prior systemic therapy for r/mCC will receive 1) TV RP2D + PEM or 2) TV RP2D + CBP; pts who received 1-2 prior treatments for r/mCC will receive TV RP2D + PEM. Additional cohorts might be added. The primary endpoint of phase 2 is ORR (RECIST v1.1). Secondary endpoints include DOR, time to response, PFS, OS, and safety.
Clinical trial identification
NCT03786081; GOG-3024.
Editorial acknowledgement
ApotheCom, San Francisco, CA, USA.
Legal entity responsible for the study
Genmab.
Funding
Genmab.
Disclosure
I.B. Vergote: Advisory / Consultancy: Advaxis; Advisory / Consultancy: Eisai; Advisory / Consultancy: MSD Belgium; Advisory / Consultancy: Roche NV; Advisory / Consultancy, Research grant / Funding (self): Genmab; Advisory / Consultancy: F. Hoffmann-La Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Millennium; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy, Research grant / Funding (self): Oncoinvent; Advisory / Consultancy: Immunogen; Research grant / Funding (self): Amgen; Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Stichting Tegen Kanker; Travel / Accommodation / Expenses: Takeda. N. Concin: Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Genmab; Travel / Accommodation / Expenses: Amgen. M.R. Mirza: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Biocad; Honoraria (self), Research grant / Funding (institution): Clovis; Honoraria (self): Geneos; Honoraria (self): Genmab; Honoraria (self): Karyopharm; Honoraria (self): Merck; Honoraria (self): Oncology Venture; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Seattle Genetics; Honoraria (self): Sera Prognostics; Honoraria (self): Sotio; Honoraria (self), Research grant / Funding (institution): Tesaro; Honoraria (self): ZaiLab; Research grant / Funding (institution): Boehringer Ingelheim. A. Malmberg: Full / Part-time employment: Genmab. L. Eaton: Full / Part-time employment: Genmab. L. Nicacio: Full / Part-time employment: Seattle Genetics. D. Lorusso: Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy: Merrimack. I. Soumaoro: Full / Part-time employment: Genmab. B.J. Monk: Honoraria (self), Advisory / Consultancy, Oncomed (honoraria/consultant): AbbVie; Honoraria (institution), Advisory / Consultancy, Oncoquest (honoraria/consultant): Advaxis; Honoraria (self), Advisory / Consultancy, Oncosec (honoraria/consultant): Agenus; Honoraria (self), Advisory / Consultancy, Perthera (honoraria/consultant): Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Pfizer (honoraria/consultant): AstraZeneca; Honoraria (self), Advisory / Consultancy, Precision Oncology (honoraria/consultant): ChemoCare; Honoraria (self), Advisory / Consultancy, Puma (honoraria/consultant): ChemoID; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Roche/Genentech (honoraria/speaker/consultant): Clovis; Honoraria (self), Advisory / Consultancy, Samumed (honoraria/consultant): Conjupro; Honoraria (self), Advisory / Consultancy, Takeda (honoraria/consultant): Eisai; Honoraria (self), Advisory / Consultancy, Vesaro (honoraria/speaker/consultant): Geistlich; Honoraria (self), Advisory / Consultancy, VBL (honoraria/consultant): Genmab; Honoraria (self), Advisory / Consultancy: ImmunoGen; Honoraria (self), Advisory / Consultancy: Immunomedics; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen/J&J; Honoraria (self), Advisory / Consultancy: Mateon (formerly Oxigene); Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Nucana. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Officer / Board of Directors, Ergomed Clinical Research (research support - institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution), Exelixis (research support - institution): AstraZeneca; Advisory / Consultancy, Henry Jackson Foundation (research support - institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution), Genentech (research support - institution): Gynecologic Oncology Group; Advisory / Consultancy, GSK (research support - institution): Myriad; Advisory / Consultancy, Research grant / Funding (institution), INC Research (research support - institution): Tesaro; Advisory / Consultancy, inVentiv Health Clinical (research support - institution): Novocure; Advisory / Consultancy, Janssen Research and Development (research support - institution): Translational Genomics/Cordgenics; Officer / Board of Directors, Ludwig Institute for Cancer Research (research support - institution): Novocure; Officer / Board of Directors, Novartis (research support - institution): Amgen; Research grant / Funding (institution), Officer / Board of Directors, PharmaMar (research support - institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution), Pfizer (research support - institution): AbbVie; Advisory / Consultancy, PRA International (research support - institution): Health Analytics; Advisory / Consultancy, Regeneron (research support - institution): Ambry; Research grant / Funding (institution), Sanofi (research support - institution): Advaxis; Research grant / Funding (institution), Serono (research support - institution): Agenus; Research grant / Funding (institution), Stemcentrx (research support - institution): Ajinomoto; Research grant / Funding (institution), Tracon (research support - institution): Array BioPharma; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Eisai.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract